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Background: The increasing demand for liver transplantation has led to considerable changes in characteristics 
of donors and recipients. In this study, the short-term and long-term mortality of HCC and non-HCC recipients 
in the UK were evaluated between 1997 and 2016. 
  
Methods: First-time elective adult liver transplant recipients in the UK were identified and four successive 
eras of transplantation were compared. Hazard ratios (aHR) comparing the impact of era on short-term (first 
90 days) and on longer-term mortality (from 90 days to 5 years) were estimated with adjustment of 
recipient and donor characteristics. 
 
Results: 1 879 HCC recipients and 7 661 non-HCC recipients were included. There was an increase in use of 
donors following circulatory death (DCD) from 0% in era 1 to 35.2% in era 4 for HCC recipients and from 0.2% 
to 24.1% for non-HCC recipients. 3-year mortality decreased from 28.3% in era 1 to 16.9% in era 4 (aHR: 0.47, 
95%CI: 0.35-0.63) for HCC recipients and from 20.4% to 9.3% (aHR: 0.44, 0.36-0.53) for non-HCC recipients. 
Comparing era 1 and era 4, improvements in short-term mortality were more marked than in long-term 
mortality both for HCC (aHR 0-90 days: 0.20, 0.10-0.39; 90 days-5 years: 0.52, 0.35-0.75; p=0.04) and for non-
HCC recipients (aHR 0-90 days: 0.32, 0.24-0.42; 90 days-5 years: 0.52, 0.40-0.67; p=0.02). 
 
Conclusion: In last 20 years, mortality after liver transplantation has more than halved, despite an increasing 






The rise in incidence of hepatocellular carcinoma (HCC) and the introduction of selection criteria that identify 
patients with HCC who are likely to achieve acceptable results with liver transplantation have led to a marked 
increase in the number of patients with HCC who receive a liver transplant.
1-5  This has put pressure on 
transplantation services in many countries because it is felt to be more difficult to cope with transplanting 
both HCC and non-HCC patients in an acceptable time frame.1 The chronic shortage of donor organs has led to 
an increase in the use of donors whose organs have a greater risk of initial poor function or failure, including 
organs donated after circulatory death (DCD).6 
 
It is currently unknown to what extent the increase in the number of liver transplants for HCC and the 
related increased use of sub-optimal donors have affected post-transplantation outcomes. A study, 
carried out in the UK including patients transplanted between 2005 and 2010, has suggested that recipients of 
a DCD liver have poorer post-transplantation outcomes.
6 However, for some patients on the waiting list, 
especially those with HCC, transplantation with a DCD liver may still offer the best chance of curative 
treatment.1 This is particularly relevant for organ allocation policies – like those used in the UK until recently – 
that do not use tumour characteristics to prioritise patients on the waiting list
7,8
 or for countries who have a 
high waiting list mortality.
9,10 
 
It has previously been shown that patients who receive a liver transplant as treatment for HCC are on average 
in a better physical condition with less signs of end-stage liver disease than patients who receive a liver 
transplantation for other reasons. This in turn may have a positive effect on short-term post-transplant 
outcomes.11 However, survival of HCC recipients in the longer term is negatively affected by recurrence of 
cancer.11 Therefore, a national population-based cohort study that explored time trends in short-term and 





PATIENTS AND METHODS 
Standard National Liver Transplant Registry 
Since 1984, the Standard National Liver Transplant Registry has assembled detailed information about all liver 
transplants performed in the seven liver transplant centres in the UK.
12 Regular checks indicate that the data 





All patients aged 17 years or older who had received a first-time elective liver transplant between 1st January 
1997 and 31st December 2016 were eligible for inclusion. Recipients were categorised into two groups: 
transplanted patients with HCC recorded in any of three diagnosis fields available in the Standard National 
Liver Transplant Registry (HCC patients) and transplanted patients with other liver disease diagnoses (non-HCC 
patients). To limit heterogeneity of the study cohort, patients who underwent transplantation for types of 
liver cancer other than HCC and those who underwent multi-visceral, super-urgent, domino or living-
related liver transplantations were excluded (Figure S1) as well as those who received a liver transplant 
for acute liver failure (including auxiliary transplantation). Patients whose survival data were missing were 
also excluded. Information on explant pathology was not available.12 
 
Patients were grouped according to date of transplantation into one of four successive 5-year transplantation 
periods (‘eras’): era 1: 1
st January 1997 – 31
st December 2001; era 2: 1
st January 2002 – 31
st December 2006; 
era 3: 1
st January 2007 – 31
st December 2011; and era 4: 1
st January 2012 – 31
st December 2016. Recipients’ 
functional status at the time of transplantation was assessed using a 5-point scale ranging from ‘able to 
carry out normal activity without restriction’ to ‘completely reliant on nursing/medical care’.15 The UKELD 
score, derived from INR, serum creatinine, serum bilirubin and serum sodium, was used to score the 
recipients’ severity of liver disease8 and values for ethnicity were dichotomised into white and non-white 
groups. Changes over time in overall donor quality were measured using the UK Donor Liver Index (DLI), 
derived from donor age, sex, height, type (DCD donor or not), serum bilirubin, smoking history, and 
whether the liver was split, with larger values representing poorer donor livers.16  
 
UK allocation policy 1997-2016 
During the study period, the allocation of DCD livers and livers donated following brainstem death (DBD) was 
organized locally and centres selected recipients according to local criteria.7-8 Patients on local waiting lists 
were prioritised according to waiting list mortality predicted on the basis of a scoring system capturing the 








Categorical variables were presented as proportions and compared using chi-squared tests and 
continuous variables were presented as means with standard deviations and compared using t-tests. 
Patients transplanted for non-HCC indications who were subsequently found to have HCC, according to 
explant pathology, were analysed on an intention-to-treat basis and remained in the non-HCC group. 
 
Kaplan-Meier methods were used to compare patient and graft survival between successive eras of 
transplantation. Follow-up was censored at 5 years after transplantation or on the last follow-up visit 
before 31
st December 2016, whatever occurred earlier. Graft failure was defined as either re-
transplantation or patient death. To account for limited follow-up in era 4, post-transplantation 
outcomes for all eras are presented up to 3 years after transplantation. 
 
Multivariable Cox regression models were used to estimate hazard ratios (HRs) that represent the 
relative differences in the primary outcomes measures of post-transplant mortality and graft failure 
between eras of transplantation. Era 1 (1997-2001) was chosen as the reference value. To determine 
whether changes in donor and recipient characteristics had influenced the impact of era of 
transplantation on post-transplant survival, HRs were initially estimated without adjustment for recipient 
or donor characteristics, then with adjustment for recipient characteristics only, and finally with 
adjustments for both recipient and donor characteristics. All characteristics included in the risk-
adjustment were based on clinical plausibility of being a potentially confounding factor for post-
transplantation mortality or graft failure.  
 
Interaction terms were included in the Cox regression models to determine whether the prognostic 
impact of era varied according to HCC status, hepatitis C virus (HCV) status in HCC patients only, and 
time-period after transplantation. Two post-transplant time periods were used: the first 90 days after 
transplantation reflecting occurrence of surgical complications, acute rejection and primary non-
function17 and from 90 days and 5 years reflecting longer term outcomes, including recurrence of primary 
liver disease.17,18 The significance of interaction terms was tested using the Wald test. 
 
Missing donor and recipient characteristics were imputed using chained equations creating ten complete 
datasets.
19 In the imputation procedure, the donor and recipient variables used in the case-mix 
adjustment were used to predict missing values, including outcome variables.20 The Cox regression 
results for each of these datasets were pooled using Rubin’s rules.
19
 Stata V15 (StataCorp, College 






Time trends in post-transplant mortality 
Between 1
st January 1997 and 31
st December 2016, 9 540 first-time single-organ elective adult liver transplants 
were performed. Over this study period, the number of adult HCC recipients almost tripled from 275 out of a 
total number of 2 117 liver transplantations (13.0%) in era 1 (1997-2001) to 727 out of a total number of 3 042 
(23.9%) in era 4 (2012-2016). The increase in total number of liver transplantations for the first 3 eras of 
transplantation was fully explained by the increase in the number of liver transplants performed in patients 
with HCC (Figure 1). In contrast, the proportion of all patients with HCC in England who received a liver 
transplant remained stable despite substantial increases in the number of patients diagnosed with HCC from 4 
029 in era 1 to 12 142 in era 4 (Figure S2). 
 
The use of DCD livers strongly increased during the study period from 0 in 275 HCC recipients and 4 in 1842 
non-HCC recipients (0.2%) in era 1 to 256 in 727 HCC recipients (35.2%) and 557 in 2 315 non-HCC recipients 
(24.1%) in era 4 (Table 1). Over the entire study period, HCC recipients were slightly more likely to receive 
donor livers that were considered steatotic or abnormal in appearance (Table 1). These findings are in line with 
the trend in the DLI, which demonstrates that liver donor quality deteriorated over time for both cohorts, but 
the deterioration was most marked for HCC patients (Table 1). 
 
There were decreases over time in the number of HCC patients who had HCV antibodies (from 49.5% in era 1 
to 41.8% in era 4) and there were corresponding decreases for non-HCC recipients (from 19.4% in era 1 to 
10.5% in era 4; Table 1). The mean time on the transplant waiting list time increased for HCC recipients from 
105.1 days (SD 112.2) in era 1 to 146.1 days (SD 149.7) in era 4 and for non-HCC recipients from 145.4 days 
(SD; 160.2) in era 1 to 164.7 days (SD 220.8) in era 4. 
 
Era-specific changes in post-transplantation outcomes 
Kaplan-Meier survival analysis 
Across the four eras of transplantation, successive improvements in post-transplantation patient and graft 
mortality were identified in both HCC and non-HCC recipients (Figure 2). In HCC recipients, 3-year patient 
mortality decreased from 28.3% (95% CI: 23.2% to 34.3%) in era 1 to 21.3% (95% CI: 17.1% to 26.3%) in era 2, 
19.0% (95% CI: 16.0% to 22.6%) in era 3 and 16.9% (95% CI: 13.5% to 21.1%) in era 4 (Figure 2a). In non- HCC 
recipients, mortality decreased from 20.4% (95% CI: 18.6% to 22.4%) in era 1 to 15.8% (95% CI: 14.2% to 
17.6%) in era 2, 11.3% (95% CI: 9.9% to 12.9%) in era 3 and 9.3% (95%CI: 7.9% to 10.9%) in era 4 (Figure 2b). 
Similarly, 3-year graft failure for HCC recipients decreased from 31.7% (95%CI: 26.4% to 37.7%) in era 1 to 
22.0% (95%CI: 18.3% to 26.3%) in era 4 (Figure 3c) and for non-HCC recipients from 24.7% (95%CI: 22.7% to 
26.8%) in era 1 to 15.0% (95%CI: 13.3% to 16.9%) in era 4 (Figure 3d).  
 
Mortality in the first 90 days after transplantation decreased from 9.1% (95% CI: 6.3% to 13.2%) in era 1 to 
2.2% (95% CI: 1.4% to 3.6%) in era 4 for HCC recipients and from to 9.6% (95% CI: 8.3% to 11.1%) in era 1 to 
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3.1% (95% CI: 2.5% to 3.9%) in era 4 for non-HCC recipients. 
 
Cox regression analysis 
Comparing era 1 to 4, post-transplant mortality in the first 5 years after transplantation decreased by 50% for 
HCC patients (unadjusted HR comparing era 1 with era 4, 0.50, 95%CI: 0.46 to 0.55; Table 2) and graft failure 
decreased by 42% (unadjusted HR 0.58, 95%CI: 0.45 to 0.76; Table 3). In non-HCC patients, mortality 
decreased by 56% (unadjusted HR comparing era 1 with era 4, 0.44, 95%CI: 0.37 to 0.53; Table 2) and graft 
failure decreased by 41% (unadjusted HR 0.59, 95%CI: 0.51-0.68; Table 3). Adjustment for recipient 
characteristics and for both recipient and donor characteristics combined had only a small impact on the time 
trends observed in post-transplant mortality or graft failure in both HCC and non-HCC recipients (Tables 2 and 
3). 
 
The effect of era on mortality and graft failure did not vary according to HCC status (p for interaction=0.27 and 
0.37, respectively) and neither did the effect of era vary in HCC recipients according to whether or not they 
had a concomitant diagnosis of HCV (p for interaction=0.12, Table S1). 
 
Over the years, In the first 90 days following transplantation, mortality decreased by 80% for HCC recipients 
(HR adjusted for both recipient and donor characteristics comparing era 1 with era 4, 0.20, 95%CI: 0.10 to 
0.39) and 68% for non-HCC recipients (adjusted HR comparing era 1 with era 4, 0.32, 95%CI: 0.24 to 0.42; 
Figures 3a and 3b; Table S2 in Supplementary Information). In the subsequent follow-up time period – from 90 
days to 5-years – decreases in mortality were not as substantial, decreasing 48% for both HCC and non-HCC 
patients (adjusted HR comparing era 1 with era 4, 0.52, 95%CI: 0.35 to 0.75 and 0.52, 95%CI: 0.40 to 0.67, 
respectively; Figures 3a and 3b; Table S2 in Supplementary Information). In both HCC and non-HCC recipients, 
the impact of era on mortality was found to be different for the two follow-up periods (p for interaction=0.04 
and 0.02, respectively). 
 
Similar differences were observed in the improvements of graft survival in the first 90 days and from 90 days 
to 5 years (Figures 3c and 4d, Table S2 in Supplementary Information) but the impact of era on graft survival 
did not differ between the two follow-up periods (p=0.13 and 0.19 for HCC and non-HCC recipients, 
respectively).  
 
Era-specific changes in causes of death 
The proportion of recipients with HCC who died of tumour recurrence within the first 5 years after 
transplantation remained stable during the first 3 eras of transplantation: era 1: 21.0% (21/100); era 2: 21.6% 
(19/88); era 3 18.5% (25/135; Table S3 in Supplementary Information). In era 4 (2012-2016), the proportion of 
HCC recipients who died of tumour recurrence was slightly lower at 14.3% (13/91). This decrease in era 4 is 
almost certainly explained by most patients in this cohort having been followed up for less than 5 years. 
Overall, 11 of the 78 HCC recipients who died of tumour recurrence (14.1%) had received a DCD liver 
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compared to 403 of the 1 801 HCC recipients who died of other reasons than tumour recurrence (22.4%, 
p=0.15). In non-HCC patients, sepsis was consistently the most common cause of death increasing from 34.5% 





In the last 20 years, the number of first-time single-organ elective liver transplantations in adult recipients 
performed in the UK has continually increased, and until recently this increase has been driven by increases in 
the transplantation of HCC patients. In the same period, increases in the use of DCD and other sub-optimal 
donor livers have been identified, particularly in patients with HCC. However, mortality in the first 5 years after 
transplantation has more than halved both for HCC patients who need a liver transplant before disease 
progresses beyond transplantable criteria and for non-HCC patients who need a liver transplant because of 
deteriorating liver function related to end-stage liver disease. There were decreases in mortality in the first 90 
days after transplantation as well as in the mortality between 90 days and 5 years. 
 
A limitation of the study was that it compared HCC recipients with a heterogeneous cohort of non-HCC 
recipients. This approach may have masked specific post-transplant mortality patterns in non-HCC 
patients related to primary liver disease. However, the dichotomy in HCC and non-HCC recipients reflects 
the fundamental difference in why patients were selected for transplantation. A liver transplant is used in 
patients with HCC as a treatment to remove a malignancy with curative intent and it is used in patient 
with end-stage liver disease as a treatment of liver failure.7,8  
 
A second limitation might be that adjustment for recipient and donor characteristics may not have fully 
captured variations in how patients were selected for liver transplantation over the 20 years of the study 
period. However, given that a wide range of characteristics were adjusted for it is rather unlikely that changes 
over time in patient selection and organ allocation criteria are major explanations for the substantial 
improvements in post-transplant survival that were observed. 
 
In addition, the time after transplantation was arbitrarily divided into two time periods: within the first 90 days 
and between 90 days and 5 years to investigate whether there were differences in time trends for short-term 
and long-term post-transplant mortality. A 90-day time period is increasingly being used to capture short-term 
surgical outcomes. A study exploring timing of surgical outcomes after hepatopancreatobiliary surgery in 4 000 
patients supports the legitimacy of the use of this 90-day limit because it demonstrated that surgery-related 
deaths accounted for all early deaths and that about 85% of all surgery-related death occurred in the first 90 
days.21 Also 90-day mortality is commonly used as a short-term outcome after liver transplantation because, in 
addition to surgical mortality, it reflects the occurrence of acute rejection and primary non-function of the 
donor liver.22 
 
Studies from the US and Europe have described changes over time in the characteristics and outcomes of 
patients receiving a liver transplant.23,24 An analysis of the United Network for Organ Sharing database in the 
US, including transplantations carried out between 1994 and 2009
23 and an analysis of the European Liver 
Transplant Registry between 1988 and 200924 demonstrated  marked increases in the number of liver 
transplantations in patients with HCC. These studies also found that HCC recipients had worse long-term 
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patient survival compared to non-HCC recipients.
23,24 However, no study could be identified that explicitly 
investigated differences in time trends of short-term and longer-term post-transplant outcomes in HCC and 
non-HCC recipients nor could a study be identified that had quantified to what extent the increased use of 
DCD livers had affected time trends in outcomes separately for HCC and non-HCC recipients. 
 
Explanation of results 
It is important to note that between 1997 and 2016 the HCC incidence increased three-fold but that the 
proportion of HCC patients who received a potentially curative liver transplant remained static. As a result, the 
number of patients with HCC who received a liver transplant has gone up accordingly. Significant increases in 
the use of DCD livers reflect increases in the total number of liver transplantations, relative decreases in the 
overall donation of DBD livers,24 and – for HCC recipients especially – the clinical requirement to provide liver 
transplantations in an acceptable time frame for patients on the waiting list. However, post-transplantation 
mortality across the 20-year study period more than halved for both HCC and non-HCC recipients. 
 
The improvements in overall patient and graft survival are most likely explained by a combination of factors, 
which initially includes the introduction of the Milan criteria followed by better matching of donors and 
recipients, developments in immunosuppression and anaesthesia, decreases in cold ischaemic time, and more 
recently the introduction of directly acting antiviral medications for patients with HCV cirrhosis.13,23 However, 
the current analysis was able to demonstrate more specifically than before that factors associated with early 
post-transplant outcomes, potentially including surgical technique and peri-operative care, are likely to have 
had a substantial impact on improved overall survival. 
 
Adjustment for differences in recipient characteristics only or for both recipients and donor characteristics had 
minimal effects on the observed time trends in the post-transplantation outcomes of HCC and non-HCC 
recipients. Instead tumour recurrence was identified as the main factor responsible for the consistently poorer 
long-term survival identified in HCC recipients.11,18 Accordingly, improvements in the longer-term survival of 
HCC recipients are more likely to be influenced by changes in the selection of HCC patients for liver 
transplantation than by donor related factors.11,18 
 
There were decreases in the number of non-HCC patients with HCV cirrhosis receiving a liver transplant but 
increases in the number of recipients transplanted for HCV-induced HCC. This is consistent with the wider 
accessibility to the newer direct acting antiviral medications leading to a cascade of events that include further 
reductions in patients with HCV requiring a liver transplant and eventual reductions in the incidence of HCV 
induced HCC.25-26 
 
Most importantly, this study demonstrated that mortality in adult patients undergoing a first-time single-
organ elective liver transplantation has more than halved in the last two decades, despite a marked increase 
in the use of DCD livers. Decreases in both short-term and long-term mortality are responsible for 
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improvements in overall survival, irrespective of whether recipients have HCC with relatively preserved liver 
function or a failure of liver function linked to end-stage liver disease. 
 
The increasing use of DCD livers over a period with substantial improvement of post-transplant outcomes is a 
guiding example for countries with a high waiting list mortality and a low DCD utilisation
10 as well as for 
countries where a high proportion of liver transplant recipients have HCC.1,23,24 In the context of the ongoing 
improvement of post-transplant outcomes, the risk of using DCD livers or livers from donors whose organs 
have a greater risk of failure must be balanced against the consequence of not using these potentially poorer 
livers with in turn higher waiting list mortality and drop-outs due to HCC progression. 
 
Between 1997 and 2016, the number of patients receiving a liver transplant increased considerably. However, 
despite the rising use of sub-optimal donor organs, post- transplantation mortality for both HCC and non-HCC 
patients has more than halved. Improvements in overall survival have been driven by decreases in both short-
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Figure 1: Time trends in the number and proportion of HCC vs versus non-HCC liver transplants performed in 
the UK, stratified by era of transplantation (n=9 540). 
 
Figure 2: Post-transplant patient and graft survival according to era of transplantation (n=9 540). 
 
Figure 3: The impact of era of transplantation on the post-transplantation outcomes from 0 to 90 days and 





Table 1: Donor and recipient characteristics according to era of transplantation. 
 ERA OF TRANSPLANTATION  









Number HCC recipients 275 318 559 727  
 Non-HCC recipients 1 842 1 785 1 719 2 315  
 
DONOR CHARACTERISTICS 
      
Female 
HCC 170% (46) 186% (59) 190% (106) 191% (138)  0.0% (0) 
Non-HCC 419% (742) 407% (725) 388% (664) 362% (831) 0.0% (0) 
Age (years) 
Mean (SD) 
HCC 46·8 (141) 46·4 (155) 48·0 (156) 50·6 (159) 0.0% (0) 
Non-HCC 43·0 (149) 45·2 (149) 46·6 (157) 50·1 (163) 0.0% (0) 
BMI (kg/M2)  
Mean (SD) 
HCC 25·4 (38) 25·6 (43) 26·6 (49) 26·5 (51) 2.1% (40) 
Non-HCC 24.8 (43) 25.6 (46) 26.0 (49) 26.4 (48) 3.8% (290) 
Trauma as cause of death 
HCC 226% (62) 135% (43) 113% (63) 89% (65) 0.0% (0) 
Non-HCC 216% (398) 154% (274) 112% (192) 60% (139) 0.0% (0) 
DCD Donor* 
HCC 00% (0) 50% (16) 254% (142) 352% (256) 0.0% (0) 
Non-HCC 02% (4) 44% (79) 158% (272) 241% (557) 0.0% (0) 
Hepatic steatosis 
HCC 470% (54) 417% (128) 476% (264) 469% (335) 10.0% (187) 
Non-HCC 366% (237) 403% (697) 445% (752) 448% (1 019) 17.2% (1 320) 
Presence of capsular damage 
HCC 173% (19) 102% (31) 121% (67) 159% (113) 10.5% (1 879) 
Non-HCC 138% (88) 135% (229) 148% (250) 131% (298) 17.8% (1 362) 
Abnormal donor liver 
appearance 
HCC 215% (59) 221% (64) 309% (136) 264% (164) 13.5% (254) 
Non-HCC 167% (307) 230% (384) 251% (348) 222% (445) 9.9% (761) 
Segmental Graft Type 
HCC 33% (9) 57% (18) 82% (46) 45% (33) 0.0-% (0) 
Non-HCC 42% (78) 79% (141) 97% (167) 85% (197) 0.0% (0) 
Cold Ischaemic Time (mins)  
Mean (SD) 
HCC 665·8 (1746) 599·1 (1636) 520·8 (1633) 490·9 (1560) 7.3% (138) 
Non-HCC 683·5 (1878) 615·0 (1692) 532·9 (1537) 510·0 (1591) 5.2% (402) 
Donor Liver Index (DLI)**  
Mean (SD) 
HCC 1.13 (0.23) 1.13 (0.23) 1.31 (0.41) 1.46 (0.49) 14.8% (278) 
Non-HCC 1.14 (0.32) 1.16 (0.28) 1.24 (0.37) 1.38 (0.45) 20.% (1539) 
 
RECIPIENT CHARACTERISTICS 
      
Female 
HCC 170% (46) 186% (59) 190% (106) 191% (138) 0.4% (8) 
Non-HCC 419% (742) 403% (725) 388% (664) 362% (831) 1.3% (103) 
Age (Years)  
Mean (SD) 
HCC 54·4 (87) 56·1 (86) 56·9 (77) 58·8 (78) 0.0% (0) 
Non-HCC 50·3 (109) 51·1 (110) 51·0 (116) 51·4 (120) 0.0% (0) 
Non-white ethnicity 
HCC 21·8% (60) 23·6% (75) 17·6% (98) 15·7% (114) 0.1% (1) 
Non-HCC 136% (251) 136% (242) 125% (214) 101% (234) 0.01% (1) 
BMI (Kg/M2)  
Mean (SD) 
HCC 26.7 (36) 27.1 (46) 26.6 (50) 28.2 (49) 2.3% (44) 
Non-HCC 25.4 (49) 26.3 (49) 27.6 (46) 27.4 (54) 4.1% (313) 
UKELD*** 
Mean (SD) 
HCC 52.1 (55) 51.5 (47) 51.1 (49) 51.0 (49) 2.3% (44) 




HCC 491% (134) 552% (175) 395% (217) 377% (271) 1.1% (20) 
Non-HCC 589% (1 081) 628% (1 116) 490% (834) 476% (1 087) 0.8% (61) 
Ascites 
HCC 375% (103) 309% (98) 284% (159) 300% (218) 0.1% (2) 
Non-HCC 618% (1 132) 557% (993) 595% (1 021) 625% (1 439) 0.4% (30) 
Previous variceal bleed 
HCC 207% (57) 223% (71) 182% (101) 139% (100) 0.6% (11) 
Non-HCC 359% (662) 332% (590) 297% (511) 267% (608) 0.8% (64) 
Encephalopathy 
HCC 98% (27) 79% (25) 128% (71) 159% (113) 1.3% (24) 
Non-HCC 220% (406) 220% (392) 329% (562) 367% (834) 0.8% (64) 
Presence of HCV antibodies 
HCC 495% (136) 436% (129) 455% (235) 418% (291) 5.6% (106) 
Non-HCC 194% (357) 169% (262) 153% (243) 105% (233) 7.1% (545) 
*Liver donated following circulatory death. 
**Includes donor factors; DCD, segmental graft, height, age, smoking status and bilirubin 
***United Kingdom Model for End-stage Liver Disease.  
****3rd level of 5-point scale assessing patient’s pre-transplantation functional status. 
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Table 2: Post-transplant mortality of HCC (n=1 879) and non-HCC recipients (n=7 661) in the first 5 years 
after liver transplantation according to era of transplantation. 
  
ERA OF TRANSPLANTATION 
 
 










P-value for the 











































































































* Adjusted for recipient characteristics: sex, age, ethnicity, BMI (Kg/M2), functional status, ascites, varices, encephalopathy, HCV status, 
UKELD, pre-transplant inpatient status, pre-transplant renal support, previous abdominal surgery. 
**Adjusted for recipient characteristics listed above and donor characteristics: sex, age, BMI (Kg/m2), cause of death, donor type (donation 




Table 3: Graft failure of HCC (n=1 879) and non-HCC recipients (n=7 661) in the first 5 years after liver 
transplantation according to era of transplantation. 
  
ERA OF TRANSPLANTATION 
 
 










P-value for the 




































































































*Adjusted for recipient characteristics: sex, age, ethnicity, BMI (Kg/M2), functional status, ascites, varices, encephalopathy, HCV status, 
UKELD, pre-transplant inpatient status, pre-transplant renal support, previous abdominal surgery. 
**Adjusted for recipient characteristics listed above and donor characteristics: sex, age, BMI (Kg/m2), cause of death, donor type (donation 
after circulatory death or donation after brain death), steatosis, capsular damage, organ appearance, graft type, cold ischaemic time. 
 
 
